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Background  :  Pulmonary  damage  resulting  from  lipid  peroxidation  is  a  principal  effect  of  paraquat  intoxication.  The 
host-defense  functions  of  surfactant  are  known  to  be  mediated  by  the  surfactant  proteins  A  and  D  (SP-A  and  SP-D, 
respectively).  The  primary  objective  of  this  study  was  to  evaluate  the  variations  over  time  in  levels  of  surfactant  protein 
and  lipid  peroxidation  (LPO)  in  lung  tissue  following  free-radical-induced  injury.
Methods  :  42  adult,  male,  Sprague-Dawley  rats  were  administered  intraperitoneal  injections  of  paraquat  (35  mg/kg 
body  weight).  SP-A  and  SP-D  levels  were  determined  via  Western  blot.  LPO  in  the  left  lung  homogenate  was 
measured  via  analyses  of  the  levels  of  thiobarbituric  acid-reactive  substances.
Results  :  LPO  levels  peaked  at  6  hours,  with  no  associated  histological  changes.  SP-D  levels  increased  until  hour 
12  and  declined  until  hour  48;  SP-D  levels  subsequently  began  to  increase  again,  peaking  at  hour  72.  SP-A  levels 
peaked  at  hour  6,  declining  thereafter.
Conclusions  :  We  suggest  that  in  the  early  phase  of  paraquat  injury,  SP-D  levels  reflect  alveolar  damage  and  that 
de  novo  synthesis  of  SP-D  takes  72  hours.  Levels  of  SP-A,  on  the  other  hand,  reflect  abnormalities  in  the  surfactant 
system  in  the  late  stage  of  paraquat  intoxication.  Surfactant  proteins  may  play  a  role  in  protecting  the  lungs  from 
reactive  oxygen  injury.  A  time-dependent  variation  has  been  observed  in  the  levels  of  surfactant  proteins  A  and  D 
following  paraquat  injury,  and  it  has  been  suggested  that  these  proteins  play  a  role  in  the  protection  of  lung  tissue 
against  ROS-induced  injuries.
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INTRODUCTION 
Paraquat  dichloride  (1,1'-dimethyl-4,4'-bipyridilium  dichloride; 
methylviologen)  is  an  effective  and  widely-employed  herbicide. 
Paraquat  is  toxic  in  humans,  with  the  lungs  being  the  principal 
target  organ,  probably  as  the  consequence  of  the  existence  of  an 
active  uptake  system
1, 2).  The  toxic  effects  of  paraquat  on  the 
lungs  result  in  pulmonary  edema,  hypoxia,  respiratory  failure,  and 
pulmonary  fibrosis.  Mortalities  as  the  result  of  paraquat  poisoning 
are  generally  attributed  to  extensive  pulmonary  injury
3).  Respiratory 
distress  occurring  during  the  early  stages  of  paraquat  poisoning 
may  be  attributable  to  impairments  of  the  surfactant  system, 
probably  resulting  not  only  from  the  paraquat  itself,  but  also  from 
the  effects  of  oxygen  free  radicals.  Pulmonary  fibrosis  in  the  late 
stage  of  paraquat  poisoning  is  generally  observed  531  days  after 
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changes  in  the  lung  that  are  comparable  to  the  lesions  observed 
in  cases  of  respiratory  distress  syndrome
4).  Pulmonary  surfactant 
is  composed  of  90%  lipid  and  10%  protein.  Four  surfactant- 
associated  proteins  exist:  surfactant  protein  A  (SP-A),  surfactant 
protein  B  (SP-B),  surfactant  protein  C  (SP-C),  and  surfactant 
protein  D  (SP-D).  Evidence  has  accumulated  over  the  past  1015 
years  that  SP-A  and  SP-D  function  as  part  of  the  first  line  of 
immune  defense  in  the  lung,  by  binding  to  pathogens,  thereby 
promoting  their  phagocytosis  and  killing  by  phagocytes
5). 
SP-A-knockout  mice  evidence  normal  lung  histology,  but  lack 
SP-A,  as  has  been  predicted,  exhibiting  an  increased  susceptibility 
to  pulmonary  infection  by  bacteria  and  viruses
6).  By  way  of 
contrast,  murine  SP-D  deficiency  unexpectedly  induces 
spontaneous  emphysematous  change  and  the  development  of 
pulmonary  fibrosis,  thereby  revealing  the  crucial  role  for  SP-D  in 
the  control  of  lung  inflammation
7, 8).  The  pathology  and 
biochemical  characterization  of  paraquat-induced  lung-injury 
models  have  been  previously  reported
9, 10).  The  present  study  was 
undertaken  in  order  to  characterize  the  variations  over  time  in 
surfactant  protein  levels,  and  to  determine  the  levels  of  lipid 
peroxidation  in  lung  tissue  following  free-radical-induced  injury.
MATERIALS AND METHODS
Animal  preparation
Adult  male  Sprague-Dawley  rats  (approximate  body  weight 
200-220  g),  which  were  maintained  on  a  standard  laboratory  diet 
and  water,  were  employed  in  this  study.  The  rats  received 
intraperitoneal  (ip)  injections  with  paraquat  (35  mg/kg  body  weight, 
Sigma  Chemical,  St.  Louis,  MO,  USA)  in  1  ml  saline.  The  animals 
were  anesthetized  via  ip  injections  of  phenobarbital  (50  mg/kg 
body  weight)  at  time  0  (control,  immediately  after  paraquat 
injection),  6  hours,  12  hours,  24  hours,  2  days,  3  days,  or  5  days 
after  the  paraquat  injection.  They  were  then  exsanguinated  via  the 
abdominal  aorta,  and  the  chest  wall  was  opened. 
Alveolar  lavage 
Three  aliquots  of  7.5  mL  saline  at  4℃ were  used  to  fill  the 
lungs.  Each  aliquot  was  flushed  into  and  out  of  the  airways  three 
times.  The  recovered  volumes  (about  85%  of  the  injected  volume) 
from  all  animals  from  the  same  experimental  group  (control,  and 
6  hours,  12  hours,  24  hours,  2  days,  3  days,  or  5  days 
postinjection)  were  pooled.
Total  protein  assay
Protein  concentrations  in  the  lavage  fluid  were  measured  via 
the  Bradford  method
11)  using  bovine  serum  albumin  as  a  standard.
Preparation  of  rat  lung  bronchoalveolar  lavage  (BAL)
BAL  fluid  was  collected  from  paraquat-treated  rats  and  diluted 
to  15  mL  in  BNC  buffer  (10  mM  sodium  borate,  pH  7.4,  150  mM 
NaCl,  3  mM  CaCl
2).  The  sample  was  centrifuged  for  10  minutes 
at  250  g  at  4℃,  followed  by  2  hours  of  centrifugation  at  27,000  g, 
and  the  resultant  pellet  was  resuspended  in  100  l  of  BNC  buffer 
and  stored  at  20℃.  Sodium  dodecyl  sulfate-  polyacrylamide  gel 
electrophoresis  and  Western  blot  analysis  were  then  conducted. 
Samples  containing  1  g  of  BAL  were  boiled  for  4  minutes  and 
applied  to  12%  NuPAGE  Novex  Bis-4,7-diphenyl-1,10- 
phenanthroline  (Tris)  gels  using  the  XCell  SureLock  Mini-Cell 
system  (Invitrogen  Life  Technologies),  in  accordance  with  the 
manufacturer's  instructions.  After  electrophoresis,  gels  were 
transferred  onto  polyvinylidine  difluoride  membranes  at  35  V  for  2 
hours,  followed  by  1  hour  of  blocking  in  phosphate-buffered  saline 
(PBS)  with  0.5%  bovine  serum  albumin  and  0.02%  Tween  20.  The 
membranes  were  then  incubated  overnight  at  4℃ in  a  primary 
antibody  against  either  SP-A  or  SP-D  (Santa  Cruz)  diluted  to 
1:500  with  PBS.  The  membranes  were  then  incubated  for  1  hour 
in  peroxidase-conjugated  secondary  antibody  diluted  to  1:1,000 
with  PBS  at  room  temperature.  The  blots  were  developed  with  an 
enhanced  chemiluminescence  detection  system  (ECL  Plus  from 
Amersham  Bioscience)
10).
Left  lung  homogenate  and  determination  of  tissue  thiobarbituric 
acid-reactive  substances  (TBA-R  S)  contents
After  the  lungs  were  perfused  free  of  blood  and  harvested  for 
lavage  fluid,  the  left  lung  was  placed  in  a  tube  and  rapidly  frozen 
in  enzyme-linked  immunosorbent  assay  buffer  and  then  stored  at 
70℃.  For  analysis,  the  tissue  was  placed  in  homogenizing  buffer 
(50  Mm  Tris  HCl,  pH  7.5,  containing  1  Methylenediaminetetraacetic 
acid,  2  mM  phenylmethylsulfonyl  fluoride,  and  2.5  mM 
N-ethylmaleimide)  at  a  defined  ratio  of  1  g  of  lung  tissue  to  9  mL 
of  homogenizing  buffer.  The  lung  tissue  was  then  homogenized 
on  ice  with  a  Polytron  (Brinkman  Instruments,  Westbury,  NY, 
USA).  The  lung  homogenates  were  spun  for  5  minutes  at  300g  to 
sediment  the  tissue  debris.  The  fluorometric  method  of  Okhawa, 
(excitation  at  532  nm;  emission  at  551  nm)  was  utilized  in  order  to 
determine  the  tissue  TBA-RS  contents
11).  A  standard  curve  was 
prepared  with  the  aid  of  tetramethoxypropane  (Sigma),  which 
under  the  assay  conditions  is  hydrolyzed  to  malondialdehyde 
(MDA).  The  detection  limit  was  0.8  mmol  MDA-thiobarbituric 
acid/ml.  TBA-RS  levels  are  expressed  as  nmol/g  of  tissue.  A  light 
microscopy  procedure  was  then  performed.  The  rats  were 
anesthetized  with  sodium  phenobarbital,  after  which  a 
thoracostomy  and  BAL  were  conducted,  and  the  right  lung  was 
sectioned.  The  right  lung  was  fixed  with  an  intratracheal  instillation 
of  4%  formaldehyde  and  1%  glutaraldehyde  in  0.1  M  phosphate 
buffer  at  a  pH  of  7.2  at  room  temperature.  For  light  microscopy, 
the  pulmonary  tissue  blocks  were  embedded  in  paraffin  and 
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Figure  1.  Variations  in  the  levels  of  surfactant  protein  D  (SP-D) 
over  time  in  rats  treated  with  paraquat.  SP-D  was  quantified  via 
Western  blot  analysis  and  data  were  expressed  as  a  fraction  of 
that  measured  in  the  control  group.  Data  are  expressed  as  the 
meanSD  values.  No  significant  differences  were  detected  in  the 
initial  SP-D  levels  among  the  groups  (as  assessed  by  ANOVA). 
The SP-D level in the 72-hour postinjection group was significantly 
higher  than  those  of  the  control,  and  the  24-hour  and  48-hour 
postinjection  groups  (*  ;  p<0.05)  (Student's  t-test).
Figure  2.  Variations  in  the  levels  of  surfactant  protein  A  (SP-A) 
over  time  in  rats  treated  with  paraquat.  SP-A  was  quantified  via 
Western blot analysis and data are expressed as a fraction of that 
measured in the control group. Data are presented as the meanSD 
values. Differences between groups were statistically significant (as 
assessed  by  ANOVA):  SP-A  levels  in  the  control,  and  6-hour  and 
12-hour  postinjection  groups  were  significantly  different  from  those 
of the 24-hour, 48-hour, and 72-hour groups (* ; p<0.05)  (Tukey's 
test)
stained  with  hematoxylin  and  eosin.
Statistical  analysis
Data  are  expressed  as  meansSD.  A  probability  value  of  p<0.05 
was  considered  to  be  indicative  of  statistical  significance,  with  all 
statistical  analyses  conducted  using  SPSS  for  Windows  (version 
12.0,  Chicago,  Illinois,  USA).  In  cases  in  which  an  F  test  indicated 
homogenous  variances,  the  Student's  t-test  was  applied;  if  not,  a 
modified  Student's  t-test  was  utilized.  Differences  between  groups 
were  tested  via  ANOVA.  For  multiple  comparisons,  Tukey's  test 
was  applied  after  ANOVA.
RESULTS
Mortality  and  clinical  observations
Eight  of  the  42  paraquat-treated  rats  died  before  sacrifice.  The 
timing  and  number  of  deaths  were  as  follows:  <24  hours,  0;  2448 
hours,  2;  4872  hours  2;  >72  hours,  4).  Some  of  the 
paraquat-treated  rats  evidenced  hypokinesia  and  anorexia.
SP-D  levels
As  is  shown  in  Figure  1,  SP-D  levels  in  the  lung  lavage 
increased  until  hour  12  after  the  paraquat  injection.  At  24  hours, 
SP-D  levels  again  declined  to  near  control  levels,  but 
subsequently  increased  again,  achieving  peak  levels  at  72  hours. 
Differences  between  groups  were  not  statistically  significant 
(p=0.66).  SP-D  levels  were  higher  at  72  hours'  posttreatment  than 
in  the  control  animals,  or  at  24  hours  and  48  hours  posttreatment 
(p<0.05).
SP-A  levels
As  is  shown  in  Figure  2,  SP-A  levels  in  lung  lavage  fluid 
achieved  peak  levels  at  6  hours  after  paraquat  injection,  after 
which  they  declined  to  levels  below  normal  (control).  Differences 
between  groups  were  statistically  significant  (p<0.05)  as  follows: 
control,  6-hour,  and  12-hour  posttreatment  groups  were 
significantly  different  from  the  24-hour,  48-hour,  and  72-hour 
posttreatment  groups  (Tukey's  test).
Lipid  peroxidation
Tissue  TBA-RS  contents  differed  significantly  between  the 
groups,  achieving  peak  levels  at  6  hours'  postinjection.  TBA-RS 
levels  in  the  control  group  differed  significantly  from  those  of  the 
6-hour  postinjection  group  (p<0.05)  (Figure  3).
Light  microscopy
As  is  shown  in  Figure  4,  the  lung  tissue  in  paraquat-treated 
rats  evidenced  inflammatory  cell  infiltration  around  the  bronchioles 
at  12  hours'  postinjection.  Inflammatory  cell  infiltration  and 
hemorrhaging  were  noted  72  hours  after  paraquat  injury.
DISCUSSION
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Figure 4. Light micrograph showing the inflammatory cell infiltration occurring after paraquat injection (hematoxylin 
and  eosin,  100).  The  control  (A)  and  6-hour  postinjection  groups  (B)  evidence  normal  cytoarchitecture.  The 
12-hour  postinjection  group  (C)  exhibits  inflammatory  cell  infiltration  around  the  bronchiole.  The  72-hour 
postinjection  group  (D)  exhibits  diffuse  lung  damage  on  the  parenchyma  and  peribronchiole.
Figure  3.  Variations  in  the  levels  of  lipid  peroxidation  over  time  in 
rats  treated  with  paraquat.  Concentrations  of  thiobarbituric 
acid-reactive  substances  (TBA-RS)  in  left  lung  tissue,  expressed  as 
a fraction of that measured in the control group. Data are expressed 
as  meanSD  values.  Differences  between  groups  were  statistically 
significant  (as  assessed  by  ANOVA):  levels  of  lipid  peroxidation  in 
the  control  group  differed  significantly  from  those  measured  in t h e  
6-hour  postinjection  group  (*  ;  p<0.05)    (Tukey's  test)
evidences  a  broad  spectrum  of  activity.  Experimental  studies 
have  indicated  that  it  accumulates  in  the  epithelial  cells  of  the 
lung  and  kidney,  eventually  resulting  in  pulmonary  fibrosis  and 
acute  renal  failure.  Lung  damage  after  paraquat  poisoning 
appears  to  be  secondary  to  derangement  of  the  pulmonary 
surfactant  system
4, 12-14),  probably  resulting  not  only  from  selective 
paraquat-induced  injury  to  type  1  and  type  2  cells,  but  also  from 
the  increased  permeability  of  alveolar  capillaries  after  oxygen- 
radical-induced  injury  to  endothelial  cells
15).  The  characteristic 
proliferative  lesions  associated  with  paraquat  poisoning,  namely 
pulmonary  fibrosis,  may  not  become  evident  until  1  week  after 
injury,  whereas  damage  resulting  from  free  radicals  commences 
immediately
16).  The  destructive  phase  is  characterized  by  the  loss 
of  type  I  and  type  II  alveolar  cells,  loss  of  surfactant,  infiltration  by 
inflammatory  cells,  and  hemorrhaging.  The  subsequent  prolifera-
tive  phase  is  characterized  by  a  loss  of  alveolar  space.  The 
fibrosis,  which  is  mediated  in  part  by  cytokines,  is  not  specific  to 
paraquat-induced  injury,  but  rather  is  observed  in  response  to  the 
acute  alveolitis  induced  by  a  variety  of  pulmonary  toxins
17).
The  overwhelming  of  tissue  defense  mechanisms  by  excessive 
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free-radical  production    may  induce  a  lipid  peroxidation  process, 
thereby  resulting  in  extensive  membrane  damage.  Several 
markers  have  been  proposed  for  the  detection  of  lipid 
peroxidation,  but  measurements  of  TBA-RS  are  probably  the 
most  widely  used  technique.  In  the  present  study,  measurements 
of  tissue  TBA-RS  levels  showed  that  oxidative  injury  began  at  an 
early  stage,  at  which  point  it  induced  no  histological  changes.  It 
has  been  established  that  the  surfactant  system  is  one  of  the 
targets  of  paraquat  toxicity.  In  a  variety  of  animal  studies, 
inhalation  of  surfactant  proved  effective  in  preserving  lung 
compliance  after  paraquat  poisoning
18).  Surfactant  is  composed 
principally  of  phospholipids,  which  are  essential  for  reducing 
surface  tension  at  the  airliquid  interface  of  the  lung.  Approximately 
10%  of  surfactant  is  protein,  and  four  surfactant  proteins  have 
been  identified:  SP-A,  SP-B,  SP-C,  and  SP-D.  SP-B  and  SP-C 
are  small  and  extremely  hydrophobic.  SP-B  is  crucial  for  the 
ability  of  surfactant  to  reduce  surface  tension
19).  The  host-defense 
functions  of  surfactant  are  mediated  principally  by  SP-A  and 
SP-D,  both  of  which  are  members  of  the  collectin  protein  family
20).
In  the  study  presented  herein,  the  concentration  of  SP-D  in  the 
lung  was  elevated  until  12  hours  after  the  paraquat  injection.  After 
1  day,  the  level  of  SP-D  had  declined  to  below  control  levels; 
they  then  began  to  increase  again,  achieving  peak  levels  at  72 
hours'  postinjection.  We  suggest  that  in  the  early  phase  after 
paraquat  injury,  the  level  of  SP-D  is  reflective  of  the  alveolar 
damage  induced  by  excessive  free-radical  production.  During  this 
phase,  the  SP-D  levels  measured  may  originate  from 
endogenous  stores;  de  novo  synthesis  of  SP-D  takes  72  hours. 
By  way  of  contrast,  SP-A  levels  peaked  at  6  hours'  postinjection, 
subsequently  declining  to  below  control  levels.  This  indicates  that 
SP-A,  which  is  intimately  associated  with  surfactant  lipid 
membranes  and  aggregates
21),  performs  a  role  different  from  that 
suggested  by  the  lung  model  of  paraquat  injury.  Experimental  data 
imply  that  SP-A  preserves  the  surface  activity  of  surfactant, 
protects  it  against  the  effects  of  serum  protein  inhibitors
22), 
contributes  to  the  stability  of  surfactant  aggregates  including 
tubular  myelin
23),  and  inhibits  phospholipase  A2  activity
24, 25).  SP-D, 
however,  appears  to  be  a  prerequisite  for  the  maintenance  of 
surfactant  homeostasis  and  lung  structure
8).  In  the  study  presented 
herein,  the  effects  of  paraquat  on  SP-A  levels  began  only  after  6 
hours'  post-injection,  thereby  suggesting  that  this  surfactant 
protein  is  affected  in  the  late  stage  after  paraquat  intoxication.
Several  factors  may  be  responsible  for  the  variable  effects  of 
paraquat  intoxication  on  SP-A  and  SP-D  over  time.  First,  SP-A 
and  SP-D  function  as  endogenous  antioxidants.  Paraquat  elicits 
the  generation  of  reactive  oxygen  species  (ROS),  which  destroy 
type  II  pneumocytes.  The  elevation  of  surfactant  protein  levels 
may  protect  the  lung  tissue  against  paraquat-induced  ROS. 
Bridges  previously  demonstrated  that  pulmonary  SP-A  and  SP-D 
are  potent  endogenous  inhibitors  of  lipid  peroxidation  and 
oxidative  cellular  injury
26).  SPD  attenuates  alveolar  macrophage 
apoptosis  in  vivo
27),  evidences  antioxidant  properties,  and  is  crucial 
to  the  modulation  of  apoptotic  cell  numbers  in  the  lung,  thereby 
suggesting  a  protective  function  for  this  surfactant  protein  in  the 
prevention  of  abnormal  alveolar  remodeling  after  oxidative  lung 
injury,  and  may  also  play  a  role  in  immune  and  lung 
developmental  processes.
Second,  in  the  early  stages  of  paraquat  intoxication,  SP-A  and 
SP-D  levels  reflect  the  extent  of  lung  injury.  Pan  previously 
demonstrated  that  serum  SP-D  is  a  marker  for  lung  injury  in  rat
28). 
In  cases  in  which  paraquat,  bleomycin,  HCl,  or  keratinocyte 
growth  factor  are  instilled  into  the  lungs,  serum  and  pulmonary 
levels  of  SP-D  are  elevated  in  BAL  fluid.  SP-D  levels  may  reflect 
the  extent  of  lung  injury  in  the  early  stages  of  paraquat  poisoning. 
In  the  later  stages,  levels  of  SP-A  may  be  the  result  of  destructive 
lung  injury  and  fibrosis.  Exogenous  surfactant  therapy  has  proven 
effective  in  several  animal  models  of  acute  lung  injury
29, 30),  and 
has  also  been  evaluated  in  humans  suffering  from  sepsis-induced 
acute  respiratory  distress  syndrome  (ARDS).
However,  clinical  responses  to  exogenous  surfactant  therapy 
have  varied  substantially.  A  large  multicenter  clinical  trial  using 
aerosolized  artificial  surfactant  was  not  determined  to  benefit 
patients  with  sepsis-induced  ARDS
29).  The  lack  of  response  to 
artificial  surfactant  may  have  been  resultant  from  the  absence  of 
surfactant  apoprotein.  In  the  paraquat-induced  lung  injury  model, 
exogenous  surfactant  tended  to  increase  the  survival  rate  and 
reduce  pulmonary  surface  wall  tension  in  rats.  In  humans,  a 
commercial  surfactant  (survanta)  may  prove  inadequate  to  treat 
patients  with  paraquat  intoxication,  as  it  does  not  include  SP-D.
Supplementation  with  surfactant  proteins  may  therefore  prove 
efficacious  in  patients  in  the  early  stages  of  paraquat  intoxication.
Our  results  demonstrate  that  there  is  a  time-dependent 
variation  in  the  levels  of  surfactant  proteins  after  paraquat  injury, 
and  suggest  that  these  proteins  perform  a  function  in  the 
protection  of  lung  tissue  from  ROS-induced  injury.
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